A phase 3, randomized, double-blind, parallel-group, multinational trial of intravenous telavancin versus vancomycin for treatment of hospital-acquired pneumonia with a focus on patients with infections due to methicillin-resistant staphylococcus aureus

Trial Profile

A phase 3, randomized, double-blind, parallel-group, multinational trial of intravenous telavancin versus vancomycin for treatment of hospital-acquired pneumonia with a focus on patients with infections due to methicillin-resistant staphylococcus aureus

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Telavancin (Primary) ; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTAIN 2
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 01 Sep 2017 Results of post hoc analysis of data from the ATLAS and ATTAIN trials assessing efficacy and safety of Telavancin in patients with Concurrent Staphylococcus aureus Bacteremia, were published in the Infectious Diseases and Therapy.
    • 01 Dec 2016 Results of ATTAIN 1 and ATTAIN 2 studies assessing the telavancin minimum inhibitory concentration values using revised broth microdilution method (rBMD) were published in the Infectious Diseases and Therapy.
    • 01 Nov 2016 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top